Antioxidant and Hepatoprotective Activity of a New Tablets Formulation from Tamarindus indica L.

Table 2

Antioxidant defense system in the liver of Sprague Dawley rats with hepatotoxicity induced by CCl₄ treated with Tamarindus indica L. tablets.

Group	MDA	SOD	CAT	GSH
	(nmol/g tissue)	(UI/mg tissue)	(UI/mg tissue)	(mg/g tissue)
I	0.47 ± 0.04	0.35 ± 0.02	0.40 ± 0.02	29.74 ± 1.98
II	1.49 ± 0.18	0.15 ± 0.01	0.13 ± 0.02	15.84 ± 1.30
III	0.66 ± 0.03	0.31 ± 0.02	0.36 ± 0.02	32.58 ± 2.68
IV	0.60 ± 0.04	0.28 ± 0.03	0.43 ± 0.02	33.01 ± 2.26
V	0.64 ± 0.03	0.33 ± 0.02	0.37 ± 0.03	29.93 ± 0.90

MDA: malondialdehyde; SOD: superoxide dismutase; CAT: catalase; GSH: reduced glutathione.
I: control group; II: CCl₄ induced hepatotoxicity group; III: Silymarin treated group; IV and V: Tamarindus indica L. tablets treated groups at doses 100 mg/kg and 200 mg/kg, respectively.
Data are expressed as mean ± SD ().
Different letters on columns indicate significant statistical differences ().